SLFN11 and small cell lung carcinoma: As previous studies have pointed out that immunotherapy is the most effective in patients with SCLC-Y or –I subtypes [19], this may simultaneously suggest that higher expression of SLFN11 is associated not only with better response to PARPi and chemotherapy but also with response to ICIs.